Incidental advanced-stage Hodgkin lymphoma diagnosed at the time of radical prostatectomy for prostatic cancer: a case report and review of literature

Antonio Di Meglio1,2*, Pier Vitale Nuzzo1,2, Francesco Ricci2, Bruno Spina3 and Francesco Boccardo1,2

Abstract

Background: Pelvic lymph nodes removed during radical retropubic prostatectomy for prostatic cancer can be found on pathological examination to harbor various unexpected pathologies. Among these, hematologic neoplasms are not infrequent. Given their frequently indolent clinical course, such neoplasms would likely have remained undiagnosed and non-life threatening. Despite this, the case we are reporting describes a rare association between two aggressive neoplasms, and it will be helpful to clinicians who encounter similar combinations of pathologies.

Case presentation: We report the challenging case of a 56-year-old, caucasian man in whom pathological assessment of pelvic lymph nodes removed during radical retropubic prostatectomy for a high-grade prostatic neoplasm revealed Hodgkin lymphoma, which was subsequently classified as stage IV. There are very few published reports of this combination of pathologies. This situation required a cautious and expert approach to delivering the most appropriate treatment with the most appropriate timing for both diseases.

Conclusion: This report describes the multidisciplinary clinical approach we followed at our institution. We have also presented a review of published reports concerning the incidence, histologic type, and management of such concurrent malignancies.

Keywords: Prostatic neoplasm, Radical prostatectomy, Hodgkin lymphoma, Hematologic neoplasm, Concurrent malignancies, CD44, Literature review

Background

Currently, radical retropubic prostatectomy (RRP) is considered the gold standard for local treatment of organ-confined prostate cancer (PCa) [1,2]. Recognizing pelvic lymph node metastases from PCa during pre-operative assessment can be problematic. Because nodal involvement is often microscopic and therefore undetectable by using standard imaging techniques and dimensional and morphologic criteria, metastatic involvement of pelvic nodes can be overlooked preoperatively; only to be discovered unexpectedly by pathologists in the resected specimen [3,4].

Several incidental findings, other than metastases from PCa, have been reported in pelvic lymph nodes evaluated at the time of RRP. These have included nodal metastases from malignancies arising in another primary site and non-metastatic disease arising directly from lymphoid tissue (i.e., various types of leukemia/lymphoma).

We describe the case of a patient who underwent surgery for a biopsy-proven high-grade PCa and had an incidental diagnosis of Hodgkin lymphoma (HL) involving pelvic lymph nodes. We then performed a systematic search of published reports concerning associations between PCa and hematologic malignancies (HM) discovered as a result of surgery for the PCa. Although several cases of concomitant HM and primary PCa have been
reported, this association is uncommon; no guidelines for the management of such patients are thus far available. Moreover, the clinical significance and prognostic impact of these malignancies in the context of PCa remains unclear.

Case presentation

Case description

A 56-year-old man was referred to our unit after undergoing RRP and bilateral pelvic lymphadenectomy at another hospital. Pathological examination had confirmed the initial diagnosis of high-grade adenocarcinoma, Gleason score 10 (5 + 5), consistent with the findings on the biopsies performed preoperatively. Additionally, it had disclosed disease extension to both lobes of the gland, apex, and seminal vesicles, and focal involvement of the resection margins (Figure 1).

None of the 30 lymph nodes removed in the procedure contained metastatic cells from the PCa. Rather and surprisingly, the larger lymph nodes were found to contain classic mixed cellularity HL. The malignant Hodgkin and Reed-Sternberg cells stained positive for cluster of differentiation (CD) 20, CD30, and CD15. Additionally, immunohistochemistry was negative for CD45, CD3, epithelial membrane antigen, and PAX5 (Figure 2).

When the patient was referred to our clinics 1 month postoperatively, his serum concentration of prostate-specific antigen (PSA) was 0.34 ng/mL (pre-surgical PSA had been 6.6 ng/mL).

A staging 18-fluoro-deoxyglucose positron emission tomography (FDG PET) scan showed nodal disease on both sides of the diaphragm with enhanced metabolic activity in the spleen and skeleton (Figure 3A). However, no tumor invasion was detected on bone marrow biopsy. A whole-body computed tomography (CT) scan confirmed axillary, mediastinal, celiac trunk, and retroperitoneal lymphadenopathies and failed to detect any bone lesions. Because the PET scan was positive at the bone level, his HL was classified as stage IV according to the
Ann Arbor classification, even though bone involvement from PCa could not be completely excluded. The patient underwent front-line combination chemotherapy with the EBVD regimen (epirubicin 35 mg/m$^2$; bleomycin 10 mg/m$^2$; vinblastine 6 mg/m$^2$; dacarbazine 375 mg/m$^2$). A multidisciplinary team of experts, including hematologists and radiation oncologists, planned and con-
curred on this approach.

After three cycles of treatment, an interim evaluation with a FDG PET scan showed no FDG-avid tissue in the previously positive sites. These data were confirmed by a whole-body CT scan, which showed shrinkage of previously enlarged lymph nodes. Thus, there was evidence that the HL had responded well to chemotherapy; however, during this time the PSA concentration had further increased up to 0.96 ng/mL (PSA doubling time 1.92 months). Therefore, anti-androgen therapy with bicalutamide, 150 mg per day, was initiated. In addition to providing evidence of HL response to chemotherapy, the radiologic images also showed interstitial pneumonia, which was considered an adverse effect of bleomycin. Hence, three more cycles of chemotherapy without bleomycin and with the addition of 40 mg of prednisone daily on days 1–5 of each cycle were scheduled.

After six cycles of chemotherapy, a FDG PET scan showed no residual disease (Figure 3B); a whole-body CT scan confirmed complete disappearance of the lymphoma lesions and resolution of the interstitial pneumonia. PSA was undetectable in his serum. Nevertheless, because of the adverse prognostic features of his PCa; namely, the high Gleason score, invasion of seminal vesicles, positive surgical margins, and the increase in PSA concentrations postoperatively (before commencement of bicalutamide therapy), on completion of chemotherapy for HL, the patient was also submitted to pelvic ir-
radiation (60 Gy were delivered in 30 fractions to the whole pelvis followed by an 18-Gy boost to the prostatic bed, which required the delivery of eight additional daily fractions). PSA continued to be undetectable in his serum up until completion of treatment and thereafter.
Bicalutamide single-agent treatment is currently being continued and the patient is being rigorously followed up with serum PSA checks 3 monthly and whole body FDG PET/CT scans 6 monthly. At the time of this report, 30 months after this patient’s referral to our clinics, there is no evidence of either HL recurrence or of PCa progression (serum PSA remains undetectable).

**Discussion**

We performed a systematic search of the PubMed database using the MeSH keywords “prostatic neoplasms”, “prostatectomy”, “lymphoma”, and “hematologic neoplasms” and identified retrospective reviews of a total of over 19,000 specimens (most of which had been obtained from patients who had undergone RRP). We identified seven studies,
designed ad hoc to assess the frequency and cause of incidental (non-metastatic) lymph node pathology discovered during RRP that had been performed between 1996 and 2007. The findings of these studies are summarized in Table 1.

We also identified three case reports of patients who had been diagnosed with a second malignant hematologic neoplasm in addition to their PCa. These isolated cases are also listed in Table 1.

In the evaluated series, the overall incidence of HM harbored by pelvic lymph nodes removed in the course of RRP had a range from 0.003% [9] to 1.2% [7]. In the great majority of these cases, the diagnosis of a HM had not been suspected preoperatively. Currently, contrast-enhanced CT scan along with MRI are the most commonly employed techniques for evaluating nodal disease pre-operatively in patients with PCa. These imaging techniques are usually reserved for patients with an intermediate or high risk of extra-prostatic and/or nodal disease dissemination [16,17]. Evaluation of lymph node metastasis is one of the major goals of CT scanning in PCa staging. However, such evaluation is limited by false-positive results and the paucity of available techniques for identifying lymph node metastasis [18].

Moreover, unsuspected abnormalities, unrelated to the known primary PCa, can be revealed during the diagnostic/staging imaging workup. Miller et al. reported discovering a clinically significant coexistent disease by CT scan in 89/1330 PCa patients (6.7%) who were to undergo radiation therapy [19].

Elmi et al. retrospectively reviewed 355 initial staging abdominopelvic CT examinations in patients with PCa for incidental findings that were unrelated to their primary disease. These “incidentalomas” were classified as being of low, moderate, or high importance, depending on the type of medical or surgical management eventually required or on their potential to adversely affect health. Seventy-five potentially significant findings were noted in 73 patients (20.6% of all patients): most were renal masses; these were confirmed to be renal cell malignancies in seven patients (1.97% of all patients). Additionally, lymphadenopathies at sites unlikely to harbor PCa metastasis were noted in 18 cases, in four of whom histopathologic examination resulted in a diagnosis of lymphoma (1.12% of all patients) [20]. Enlarged lymph nodes were detected in 102 patients; only 18 of these were in sites uncommonly affected by PCa metastasis (mainly mesenteric). Accordingly, Coakley et al. suggested that a diagnosis of lymphoma should be considered in patients with PCa and imaging findings of mesenteric lymphadenopathies [21].

He et al. reported a <1% incidence of metastases from PCa in pelvic lymph nodes [11]. This rate of positivity is unusually low compared with major retrospectively assessed series reported by Roehl et al. and Daneshmand et al.: these authors cite an incidence of enlarged lymph nodes in typical PCa locations in the range of 5.8% [22] to 12.1% [23] in series of 3478 and 1972 patients, respectively, who had undergone RRP and lymph node dissection. However, Partin et al. have reported an even larger series of 5079 cases, considerably more than in either Roehl et al. or Daneshmand et al.’s series. These authors reported pathologically confirmed metastatic involvement by PCa of lymph nodes in 2% of the 5079 lymph node dissections performed [24].

Winstanley et al. have reported other findings apart from hematolymphoid pathology in enlarged pelvic nodes in patients undergoing RRP. Most such lymph nodes findings did not harbor neoplasms but were affected by other pathologies, including sinus histiocytosis, non-caseating granulomas, and foreign body reactions. Therefore, pathologists should be aware of these possibilities, to arrive at the correct diagnosis [9].

In the present case, our patient had not undergone any pre-surgical staging, probably because of his good general health and young age. In regard to age, Elmi et al. reported that the overall rate of incidental findings is not significantly different in patients aged <65 versus >65 years. However, they reported that patients aged more than 65 years have a higher rate of second neoplasms/synchronous malignancies than younger patients [20]. These findings are not relevant to our patient, who was aged less than 65 years.

Preexisting co-morbidities can influence treatment choices in patients with newly diagnosed PCa [25]. Though possible, incidental discovery of life-threatening conditions that may force clinicians to delay or modify the scheduled treatment for PCa is rare: imaging overuse can lead to over-diagnosis of subclinical conditions that would never become overt during a patient’s lifetime; this is a worldwide issue [26].

When discovered incidentally, HM are usually at an extremely early stage, have limited spread, and are asymptomatic [7,11]. Although our patient was asymptomatic, he had stage IV HL involving lymph nodal stations on both sides of the diaphragm, as well as extranodal sites (spleen and skeleton). It is extremely rare to find such advanced disease incidentally. Of the cases identified by Eisenberger et al. in over 4000 procedures, none had diffuse and/or bulky disease [8].

Taking together, only six of 89 reported cases of incidentally discovered HM required an aggressive approach. Most reported patients with incidentally discovered HM had low-grade follicular non-Hodgkin lymphoma or small lymphocytic lymphoma/chronic lymphocytic leukemia. Considering the indolent nature of these conditions and the associated expected long-term survival, the decision to
| Authors and year     | Number of radical prostatectomies (Number of lymph node dissections performed) | Total number of concurrent hematolymphoid malignancies (Overall incidence) | Encountered Hematolymphoid malignancy | Treatment required for hematologic malignancy |
|---------------------|---------------------------------------------------------------------------------|--------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|
| Donohue et al. 1996 [5,6] | 225 (N.A.)                                                                      | 3 (1.2%)                                                                | Lymphoma NOS                         | N.A.                                        |
| Terris et al. 1997 [7]       | 1092 (all patients)                                                             | 13 (1.2%)                                                               | 3 HL                                 | Pelvic and abdominal external beam irradiation |
|                        |                                                                                 |                                                                          | 1 HCL                                | Aggressive tp NOS                          |
|                        |                                                                                 |                                                                          | 1 CLL                                 | No tp                                       |
|                        |                                                                                 |                                                                          | 6 SLL                                 | No tp                                       |
| Eisenberger et al. 1999 [8]   | 4319 (all patients)                                                             | 10 (0.2%)                                                               | 8 Lymphocytic lymphoma               | Single-agent CT                             |
|                        |                                                                                 |                                                                          | 2 FL                                  | N.A.                                        |
|                        |                                                                                 |                                                                          | 1 FL                                  | N.A.                                        |
|                        |                                                                                 |                                                                          | 12 Non-neoplastic findings\(^1\)      | N.A.                                        |
| Winstanley et al. 2002 [9]     | 1001 (854)                                                                      | 15 (1.8%)                                                               | 2 SLL/CLL                            | N.A.                                        |
|                        |                                                                                 |                                                                          | 3 neoplastic (0.003%)                | N.A.                                        |
|                        |                                                                                 |                                                                          |                                      | N.A.                                        |
| Weir et al. 2003 [10]          | 6143 (all patients)                                                             | 18 (0.3%)                                                               | 18 SLL/CLL                           | N.A.                                        |
|                        |                                                                                 |                                                                          |                                      | N.A.                                        |
| He et al. 2007 [11]           | 1500 (1150)                                                                     | 13 (1.13%)                                                              | 9 SLL/CLL                            | N.A.                                        |
|                        |                                                                                 |                                                                          | 3 MZL                                 | N.A.                                        |
|                        |                                                                                 |                                                                          | 1 MCL                                 | Aggressive CT NOS                          |
| Chu et al. 2005 [12]          | 4831 \(^3\) (N.A.)                                                             | 29 (0.6%)                                                               | 18 incidental cases                  | N.A.                                        |
|                        |                                                                                 |                                                                          | 13 SLL/CLL                           | N.A.                                        |
|                        |                                                                                 |                                                                          | 3 MZL                                 | N.A.                                        |
|                        |                                                                                 |                                                                          | 1 MCL                                 | N.A.                                        |
|                        |                                                                                 |                                                                          | 11 concurrent known lymphoma\(^2\)    | N.A.                                        |
|                        |                                                                                 |                                                                          | 4 SLL/CLL                            | N.A.                                        |
|                        |                                                                                 |                                                                          | 4 FL                                  | N.A.                                        |
|                        |                                                                                 |                                                                          | 2 MCL                                 | N.A.                                        |
|                        |                                                                                 |                                                                          | 1 DLBCL                               | N.A.                                        |

**Isolated case reports**

| Isolated case reports | Encountered Hematolymphoid malignancy | Treatment required for hematologic malignancy |
|-----------------------|---------------------------------------|---------------------------------------------|
| Carson H et al. 1996 [13] | 1 SLL/CLL                            | N.A.                                        |
| Mydlo et al. 2001 [14]     | 1 lymphoma NOS                        | N.A.                                        |
| Drinis et al. 2009 [15]     | 1 SLL/CLL                            | No tp                                       |

**Abbreviations used:** NOS not otherwise specified, tp therapy, N.A. not available, CT chemotherapy, HL Hodgkin lymphoma, HCL hairy cell leukemia, CLL chronic lymphocytic leukemia, SLL small lymphocytic lymphoma, MZL marginal zone lymphoma, MCL mantle cell lymphoma.

\(^1\)Including sinus histiocytosis, non-caseating granulomas, foreign body reactions.

\(^2\)Prostate and pelvic lymph nodes involved as part of a systemic disease.

\(^3\)Specimens were from 3405 biopsies, 266 transurethral resections, and 1160 prostatectomies.
delay treatment until symptoms developed or disease-related complications occurred was made in the majority of patients reported [27].

No clinical management algorithms have yet been defined for synchronous occurrence of PCa and HL; the impact of such a double diagnosis on clinical outcome is unknown. Most authors suggest to treat the more aggressive condition first, thus improving the overall status of the patient and facilitating a better response of the second disease to therapy [28]. In our case, treatment decisions were jointly made by a panel of experts. Because HL appeared to be both the more aggressive of the two conditions and the disease in which cure was more likely to be achieved, combination chemotherapy with the EBVD regimen was initiated as soon as the patient had recovered from his surgery; complete remission of the disease was achieved within a few months.

To avoid any interference with the treatment for his lymphoma, our panel of experts decided to postpone pelvic radiotherapy, even though it was robustly indicated in view of the locally advanced stage of PCa and microscopic residual disease. The decision to postpone this treatment was supported by the prompt PSA response to the anti-androgen therapy initiated after the first two chemotherapy cycles. Though no randomized studies have demonstrated clear superiority for immediate treatment of biochemical recurrence with radiation or hormonal therapy, several retrospective studies have shown that anti-androgen therapy prolongs time to metastasis and probably PCa-specific survival [29,30].

Despite the adverse histologic features and high Gleason score of our patient’s PCa, he has had no evidence of metastatic disease and no increase in PSA since completing pelvic radiotherapy.

As already mentioned, it is not clear yet whether the co-existence of a malignant lymphoma can alter per se the natural history of PCa.

Drinis et al. have raised the intriguing possibility that lymphomas could potentially protect against PCa progression. According to these authors, such protection could result from the over-expression of circulating transmembrane molecule CD44 in leukemia and lymphoma.

Figure 4 Seminal vesicle infiltration by adenocarcinoma of the prostate (Hematoxylin/Eosin and CD44 staining). (A,C) Hematoxylin and eosin stained photomicrographs showing left seminal vesicle infiltration by poorly differentiated adenocarcinoma of the prostate (10x and 40x magnification, respectively) (B,D) Photomicrographs showing positive CD44 staining of left seminal vesicle and negative staining CD44 staining of adenocarcinoma of the prostate (10x and 40x magnification, respectively).
patients [15]. Some experimental studies support a tumor suppressor function of CD44 in lymphomas; silencing of CD44 expression may facilitate lymphoma genesis [31]. In contrast, circulating concentrations of this protein appear to be decreased in advanced and metastatic PCa, apparently contributing to tumor progression [32,33].

Gao et al. have also suggested that CD44 is a “metastatic suppressor gene” in PCa. [34-36]. The biological role of CD44 might not be identical in all organs and tumors. In tissues that do not normally express CD44, its acquired expression probably correlates with an adverse outcome, the CD44 having growth- and metastasis-promoting actions [37-39].

In light of the above data, we performed CD44 immunostaining on the surgical specimens obtained from our patient during prostatectomy and lymph node dissection (Figure 4). The normal prostatic tissue stained positive for CD44, whereas the PCa tissue did not. The peritumoral stroma, seminal vesicles, and sites of perineural invasion were mildly CD44 positive. Lymph nodes involved by lymphoma also stained positive for CD44. These findings support the theory that CD44 is expressed by normal prostatic epithelium and that capacity for expression is lost during the alterations in structural differentiation that occur in the course of the transition to neoplastic tissue. Whether CD44 might be a prognostic marker indicating the malignant potential of neoplasm would be difficult to determine because a standard histologic scoring system that includes CD44 assay would be problematic because of the heterogeneity and available isoforms of this receptor [40]. Additionally, the interaction between CD44 expression by lymphoma cells and PCa cells remains unclear; further investigation is needed to assign a definite role to this transmembrane protein [41,42].

Conclusions
Apart from some speculations, we are not able to take a definitive stance about how the concurrent presence of a HM may affect or interfere with the natural history of PCa. What we can confidently state is that, in the present patient, the concurrent presence of a poor-risk PCa not only did not hamper treatment of the unexpected and newly diagnosed advanced-stage HL, but did not even hinder achievement of complete remission of the latter and long-term relapse-free survival.

Consent
Written informed consent was obtained from the patient for publication of this case report and the accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations
CD: Cluster of differentiation; FDG PET: 18-fluoro-deoxyglucose positron emission tomography; HL: Hodgkin lymphoma; HM: Hematologic malignancy; PCa: Prostatic carcinoma; PSA: Prostate-specific antigen; RRP: Radical retropubic prostatectomy.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
DMA participated in the study conception, acquisition and interpretation of data, and in drafting the manuscript. NPV participated in the study conception and made substantial contributions to the acquisition and interpretation of data. RF participated in updating the patient’s history and helped in the interpretation of data. SB carried out the immunohistochemistry analysis and evaluation of staining. BF made substantial contributions to conception, design, analysis, and interpretation of data, was also involved in drafting the manuscript and revising it critically for important intellectual content, and in giving final approval to the manuscript. All authors have read and approved the final version of the manuscript.

Acknowledgments
The authors gratefully thank Dr. Bandelloni Roberto (Histopathology Unit, Hospital Galliera, Genoa, Italy) for the initial pathologic diagnosis and for providing tissue samples and Drs. Salvi Sandra and Roccardo Simona (IRCCS San Martino University Hospital - IST National Cancer Research Institute, Histopathology and Cytology Unit, Genova, Italy) for performing immunostaining assays on surgical samples.

Author details
1IRCCS San Martino University Hospital, IST National Cancer Research Institute, Academic Unit of Medical Oncology, Genoa, Italy. 2Department of Internal Medicine (DMI), University of Genova School of Medicine, Genoa, Italy. 3IRCCS San Martino University Hospital, IST National Cancer Research Institute, Histopathology and Cytology Unit, Genova, Italy.

Received: 17 April 2014 Accepted: 31 July 2014
Published: 26 August 2014

References
1. Lu-Yao GL, Yao SL: Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997, 349:906–910.
2. Wilt TJ, Brawer MK, Jones KM: Prostate Cancer Intervention versus Observation Trial (PIVOT) study group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012, 367:203–213.
3. Flanagan RC, McKay TC, Olson M: Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy. Urology 1996, 48:428–432.
4. Levan Z, Gonzalez JA, Dickino AC: Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer? Br J Urol 1995, 75:778–781.
5. Donohue RE: Second malignancies in adenocarcinoma of the prostate. In Sixth International Prostate Cancer Update. Colorado: Bever Creek; 1996.
6. Donohue RE: Causes of death in a radical prostatectomy series. In Sixth International Prostate Cancer Update. Colorado: Bever Creek; 1996.
7. Terris MK, Hausdorff J, Freiha FS: Hematolymphoid malignancies diagnosed at the time of radical prostatectomy. J Urol 1997, 158:1457–1459.
8. Eisenberger CF, Walsh PC, Eisenberger MA: Incidental non-Hodgkin’s lymphoma in patients with localized prostate cancer. Urology 1999, 53:175–179.
9. Winstanley AM, Sandison A, Bott SR: Incidental finding sinus pelvic lymph nodes at radical prostatectomy. J Clin Pathol 2002, 55:623–626.
10. Weir EG, Epstein JJ: Incidental small lymphocytic lymphoma/chronic lymphocytic leukemia in pelvic lymph nodes excised at radical prostatectomy. Arch Pathol Lab Med 2003, 127:567–572.
11. He H, Cheng L, Weiss LM: Clinical outcome of incidental pelvic node malignant B-cell lymphomas discovered at the time of radical prostatectomy. *Leuk Lymphoma* 2007, 48:1976–1980.

12. Chu PG, Huang Q, Weiss LM: Incidental and concurrent malignant lymphomas discovered at the time of prostatectomy and prostate biopsy: a study of 29 cases. *Am J Surg Pathol* 2005, 29:693–699.

13. Carson HJ: Unexpected synchronous non-Hodgkin’s lymphoma encountered during the treatment of a previously-diagnosed carcinoma: report of three cases. *Leuk Lymphoma* 1996, 23:625–629.

14. Mydlo JH, Gerstein M: Patients with urologic cancer and other nonurologic malignancies: analysis of a sample and review of the literature. *Urology* 2001, 58:864–869.

15. Dirrisi S, Finkelstein MP, Tortorella DC: Five-year prognosis after radical prostatectomy in a patient with localized prostate cancer and incidental non-Hodgkin’s lymphoma. *Urol Int* 2001, 66:105–107.

16. D’Amico AV, Whittington R, Malkowicz SB: Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. *J Clin Oncol* 1999, 17:168–172.

17. D’Amico AV, Whittington R, Malkowicz SB: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. *JAMA* 1998, 280:969–974.

18. Tarcan T, Türkeri L, Biren T: The effectiveness of imaging modalities in clinical staging of localized prostatic carcinoma. *Int Urol Nephrol* 1996, 28:773–779.

19. Miller JS, Puckett ML, Johnstone PA: Frequency of coexistent disease at CT in patients with prostate carcinoma selected for definitive radiation therapy: is limited treatment-planning CT adequate? *Radiology* 2000, 215:41–44.

20. Emini A, Tabatabaei S, Talab SS: Incidental findings at initial imaging workup of patients with prostate cancer: clinical significance and outcomes. *AJR Am J Roentgenol* 2012, 199:1305–1311.

21. Coakley FV, Lin RY, Schwartz LH: Mesenteric adenopathy in patients with prostate cancer: frequency and etiology. *AJR Am J Roentgenol* 2002, 178:125–127.

22. Roehl KA, Han M, Ramos CG: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. *J Urol* 2004, 172:910–914.

23. Daneshmand S, Quek ML, Stein JP: Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. *J Urol* 2004, 172:2252–2255.

24. Partin AW, Mangold LA, Lamm DM: Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. *Urology* 2001, 58:843–848.

25. Tewari A, Johnson CC, Divine G: Long-term survival probability in men with clinically localized prostate cancer case-control, propensity modeling study stratified by race, age, treatment and comorbidities. *J Urol* 2004, 171:1513–1519.

26. Heidenreich A, Aus G, Bolla M: European Association of Urology. EAU guidelines on prostate cancer. *Eur Urol* 2008, 53:e68–80.

27. Young MP, Kirby RS, O'Donoghue EP: Accuracy and cost of intraoperative lymph node frozen sections at radical prostatectomy. *J Clin Pathol* 1999, 52:925–927.

28. Mydlo JH, Agins IA, Donohoe J: A review of urologic cancer patients with multiple primary malignancies. *World J Urol* 2001, 19:240–243.

29. Sung J, Esplitu J, Segall GM: Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer. *BJU Int* 2003, 92:24–27.

30. Jadvar H: Prostate cancer: PET with 18 F-FDG, 18 F- or 11C-acetate, and 18 F- or 11C-choline. *J Nucl Med* 2011, 52:81–89.

31. Eberth S, Schneider B, Rosenwald A: Epigenetic regulation of CD44 in Hodgkin and non-Hodgkin lymphoma. *BMC Cancer* 2010, 10:15317.

32. Noordzij MA, van Steenbrugge GJ, Schröder FH: Decreased expression of CD44 in metastatic prostate cancer. *Int J Cancer* 1999, 22:841–848.

33. Hao J, Madigan MC, Khati A: In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147. *PloS One* 2012, 7:e40716.

34. Gao AC, Lou W, Dong JT: CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. *Cancer Res* 1997, 57:846–849.

35. Gao AC, Lou W, Steeiman JP: Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate. *Cancer Res* 1998, 58:2350–2352.

36. Noordzij MA, van Steenbrugge GJ, Verkaik NS: The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. *Clin Cancer Res* 1997, 3:805–815.

37. Negi LM, Talegaonkar S, Jaggii V: Role of CD44 in tumour progression and strategies for targeting. *J Drug Target* 2012, 20:561–573.

38. Günther U, Hoffmann M, Rudy W: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. *Cell* 1991, 65:13–24.

39. Kaufmann M, Heider KH, Sirin HP: CD44 variant exon epitopes in primary breast cancer and length of survival. *Lancet* 1993, 345:615–619.

40. Eksi S, Ayhan A, Kendi S: Determination of prognosis in patients with prostate cancer treated with radical prostatectomy: prognostic value of CD44v6 score. *J Urol* 2002, 167:2037–2041.

41. Martin P: CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1: biomarkers in search of validation in lymphomas. *Leuk Lymphoma* 2012, 53:1–2.

42. Ghosh SC, Neslihan Alpay S, Kloostgaard I: CD44: a validated target for improved delivery of cancer therapeutics. *Expert Opin Ther Targets* 2012, 16:635–650.